CDNA vs. SERA, CELC, CSTL, FLGT, BDSX, BNR, PSNL, VRDN, VCYT, and OSUR
Should you be buying CareDx stock or one of its competitors? The main competitors of CareDx include Sera Prognostics (SERA), Celcuity (CELC), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Biodesix (BDSX), Burning Rock Biotech (BNR), Personalis (PSNL), Viridian Therapeutics (VRDN), Veracyte (VCYT), and OraSure Technologies (OSUR).
Sera Prognostics (NASDAQ:SERA) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
In the previous week, Sera Prognostics had 2 more articles in the media than CareDx. MarketBeat recorded 19 mentions for Sera Prognostics and 17 mentions for CareDx. Sera Prognostics' average media sentiment score of 0.62 beat CareDx's score of 0.21 indicating that CareDx is being referred to more favorably in the news media.
54.6% of Sera Prognostics shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by company insiders. Comparatively, 4.2% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
CareDx received 415 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 66.72% of users gave CareDx an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.
Sera Prognostics has higher earnings, but lower revenue than CareDx. Sera Prognostics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
CareDx has a net margin of -66.59% compared to CareDx's net margin of -11,843.79%. CareDx's return on equity of -46.35% beat Sera Prognostics' return on equity.
Sera Prognostics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, CareDx has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
Sera Prognostics presently has a consensus target price of $2.75, indicating a potential downside of 70.30%. CareDx has a consensus target price of $14.00, indicating a potential downside of 5.60%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe CareDx is more favorable than Sera Prognostics.
Summary
CareDx beats Sera Prognostics on 10 of the 18 factors compared between the two stocks.
Get CareDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
